Hepatocellular carcinoma autoantibodies analyzed proteomically

"To detect autoantibodies that could be diagnostic markers for HCC, we analyzed serum autoantibodies comprehensively that showed immunoreactivity to proteins in tumor tissue obtained from patients with HCC. Fifteen paired samples of HCC tissue and corresponding nontumorous liver tissue as well as five normal liver tissue samples were used in the study," wrote M. Takashima and colleagues, Yamaguchi University. They explained, "A combination of proteomics and SEREX (serologic analysis of recombinant cDNA expression libraries) technique was used. Tissue proteins were separated by 2-DE, transferred onto PVDF membranes, and immunoblotted with autologous sera." "By comparing each immunoblot pattern, we identified four immunoreactive spots with stronger staining intensity in tumorous tissues than in corresponding nontumorous tissues and in normal liver tissues. Matched proteins on 2-DE gels were identified by LC-MS/MS. These immunoreactive proteins were heat shock 70 kDa protein 1 (HSP70), glyceraldehyde 3-phosphate dehydrogenase, peroxiredoxin, and manganese superoxide dismutase (Mn-SOD). "In HCC sera, occurrences of autoantibodies against these proteins were 7/15 (46.7%), 5/15 (33.3%), 5/15 (33.3%), and 6/15 (40.0%), respectively, whereas 2/20 (10.0%), 7/20 (35.0%), 0/20 (0.0%), and 2/20 (10.0%) were in control sera," wrote the researchers. "Immunoblot analysis using commercially available purified proteins was performed to confirm the specificity of autoantibodies. By statistical analysis, autoantibodies against FISP70, peroxiredoxin, and Mn-SOD showed significantly high-frequency immunoreaction in HCC sera," the scientists wrote. The authors concluded, "The three antibodies were considered patient-specific antibodies in HCC and may be candidate diagnostic biomarkers for HCC." "Source":[ http://www.spectroscopynow.com/coi/cda/detail.cda?id=14540&type=News&chId=4]

---